Candriam S.C.A. Caribou Biosciences, Inc. Transaction History

Candriam S.C.A.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 05, 2024	SELL	$1.62 - $5.05 $842,400 - $2.63 Million	-520,000 Reduced 45.41%	625,063 $1.03 Million
Q1 2024 May 03, 2024	BUY	$4.82 - $8.26 $1.37 Million - $2.35 Million	285,039 Added 33.14%	1,145,063 $5.89 Million
Q4 2023 Feb 14, 2024	BUY	$3.58 - $6.25 $3.08 Million - $5.38 Million	860,024 New	860,024 $4.93 Million
Q1 2023 May 12, 2023	BUY	$4.3 - $7.78 $367,890 - $665,625	85,556 New	85,556 $454,000

135

52.6M

148K

70.7K

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $110M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.